Design, Synthesis and Docking studies of New Quinazolinone Derivatives as Anti-HIV-1 Agents

The Human Immunodeficiency Virus (HIV) infection is a global health challenge that creates an urgent need todevelop new therapeutic agents. In this work, a new group of quinazolinone derivatives were designed andsynthesized and evaluated their anti-HIV activity. The antiviral assay revealed that some analogues inhibited HIVreplication in the cell culture. A docking study using the later crystallographic data available for PFV integraseincluding its complexes with Mg2+ and dolutegravir, showed that the designed compounds bind into the active siteof integrase enzyme such that both carbonyl groups chelate Mg2+ ions. Interestingly, all of the synthesizedcompounds were found to present no significant cytotoxicity at a concentration of 100 μM. According to the antiHIV evaluation results, the compound 10f was found as the most active with the inhibition rate of 38%. Therefore,these compounds can provide a very good basis for the development of new anti-HIV agents.